BlackRock Fund Advisors recently announced the acquisition of new stake in Advaxis Inc. (NASDAQ:ADXS). The institutional investor has increased its shareholding in the Healthcare company by 2.70% to 0.87 million shares with purchase of 22909.0 shares. This fresh investment now brings its stake to 1.41% valued currently at $0.5 million. In addition, The Vanguard Group, Inc. raised its holdings by 5900.0 to 0.81 million shares.
With over 1.18 million Advaxis Inc. (ADXS) shares trading Monday and a closing price of $0.45 on the day, the dollar volume was approximately $0.53 million. The shares have shown a negative weekly performance of -12.28% and its price on 08/24/20 lost nearly -2.64%. Currently, there are 60.57M common shares owned by the public and among those 48.23M shares have been available to trade.
Incidentally, analysts’ outlook for the Advaxis Inc. stock is 2.00 for the next 12 months.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 3,000 shares.
The top 3 mutual fund holders in Advaxis Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Bridgeway Ultra Small Company Mar. Vanguard Extended Market Index Fu owns 0.81 million shares of the company’s stock, all valued at over $0.47 million. Bridgeway Ultra Small Company Mar bought 0.16 million shares to bring its total holdings to over 0.16 million shares at a value of $90248.0. Bridgeway Ultra Small Company Mar now owns shares totaling to 0.25% of the shares outstanding.
Shares of Advaxis Inc. (NASDAQ: ADXS) opened at $0.47, up $0.01 from a prior closing price of $0.46. However, the script later closed the day at $0.45, down -2.64%. The company’s stock has a 5-day price change of -12.28% and -35.48% over the past three months. ADXS shares are trading -47.53% year to date (YTD), with the 12-month market performance up to 11.91% higher. It has a 12-month low price of $0.21 and touched a high of $1.48 over the same period. Currently, 1.18 million shares have been traded, compared to an average intraday trading volume of 1.17 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -18.01%, -21.38%, and -34.75% respectively.
Institutional ownership of Advaxis Inc. (NASDAQ: ADXS) shares accounts for 19.70% of the company’s 60.57M shares outstanding. Mutual fund holders own 2.34%, while other institutional holders and individual stakeholders account for 9.36% and 0.11% respectively.
It has a market capitalization of $28.73M and a beta (3y monthly) value of 3.59. The earnings-per-share (ttm) stands at -$1.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.91% over the week and 6.60% over the month.
Analysts forecast that Advaxis Inc. (ADXS) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2021. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.96 a year ago.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Advaxis Inc. (ADXS) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ADXS, a number of firms have released research notes about the stock. Barclays stated their Overweight rating for the stock in a research note on August 03, 2016, with the firm’s price target at $15-$20. Barclays coverage for the Advaxis Inc. (ADXS) stock in a research note released on September 22, 2015 offered a Overweight rating with a price target of $40. Guggenheim was of a view on September 11, 2015 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on June 16, 2015, issuing a price target of $25- $30. Jefferies on their part issued Buy rating on May 15, 2015.